---
title: 'RareAgent: Multi-Agent Reasoning for Drug Repurposing'
url: https://www.emergentmind.com/topics/rareagent
type: topic
---

# RareAgent: Multi-Agent Reasoning for Drug Repurposing

RareAgent most directly denotes a self-evolving multi-agent reasoning framework for drug repurposing in rare diseases, introduced for the sparse-zero bipartite setting in which neither the queried disease nor the candidate drug has informative drug–disease graph connectivity. In that formulation, the system shifts the task from static score prediction on a biomedical knowledge graph to active construction, adversarial critique, and iterative refinement of task-specific evidence graphs. At the same time, closely related literature uses near-identical names for distinct rare-disease agent systems and, in one case, as a mistaken variant of an unrelated security defense, so the term has acquired a measure of nomenclatural ambiguity across recent arXiv work [2510.05764][2412.12475][2507.15867][2607.00733][2506.08336].

## 1. Terminology and referential ambiguity

In the strict sense, **RareAgent** is the system introduced in "RareAgent: Self-Evolving Reasoning for Drug Repurposing in Rare Diseases" [2510.05764]. However, adjacent papers use similar labels in ways that can easily be conflated.

| Term | Referent | arXiv id |
|---|---|---|
| RareAgent | Drug repurposing via self-evolving multi-agent reasoning | 2510.05764 |
| RareAgents | MDT framework for rare-disease diagnosis and treatment | 2412.12475 |
| RDMA | Rare Disease Mining Agents for EHR note mining | 2507.15867 |
| "RareAgent" in AgentODE details | Informal guidance label for rare-disease modeling agents | 2607.00733 |
| “RareAgent” as mistaken variant | Actually **ReAgent**, a backdoor defense for LLM agents | 2506.08336 |

The distinction matters because the singular **RareAgent** paper addresses **drug repurposing** under graph sparsity, whereas **RareAgents** addresses **clinical MDT-style diagnosis and medication recommendation**, **RDMA** addresses **rare-disease and phenotype mining from EHR notes**, and **AgentODE** addresses **mechanistic ODE discovery and parameter inference from population-level summary statistics**. In the ReAgent paper, the authors explicitly state that the string “RareAgent” does not appear in the paper and should be treated as an informal or mistaken variant of **ReAgent** [2510.05764][2412.12475][2507.15867][2607.00733][2506.08336].

## 2. RareAgent in rare-disease drug repurposing

Drug repurposing aims to find new therapeutic indications for existing drugs, and the RareAgent paper frames this as especially important for rare diseases because fewer than 10% of thousands of rare diseases have approved therapies. The work targets the **sparse-zero bipartite setting**, where standard KG completion and message-passing GNNs have little reliable signal because both endpoints of a candidate drug–disease link are nearly isolated in the graph [2510.05764].

The underlying biomedical knowledge graph is written as

$$
G_K = (\mathcal{E}, \mathcal{R}, \mathcal{T}),
$$

where $\mathcal{E}$ are entities, $\mathcal{R}$ are relation types, and $\mathcal{T}$ are triples. A repurposing query is

$$
Q = (q, r_{\text{target}}),
$$

with $q$ a drug or disease and $r_{\text{target}}$ the target relation, such as indication or contraindication. The neighborhood of an entity is

$$
\mathcal{N}(e) = \{ v \in \mathcal{E} \mid (e,r,v)\in\mathcal{T} \ \lor \ (v,r,e)\in\mathcal{T} \},
$$

and the sparse-zero regime is defined by

$$
|\mathcal{N}(q)| \le \epsilon_1 \quad \land \quad |\mathcal{N}(c)| \le \epsilon_2.
$$

This formulation is central to the paper’s argument: when both sides of a candidate link are degree-zero or near degree-zero in the drug–disease bipartite subgraph, ordinary message passing, KG embedding, and rule mining are structurally limited. The paper further argues that densifying KGs with similarity or co-mention edges introduces spurious links, dilutes informative edges, and can yield over-smoothing, over-squashing, and poor generalization. RareAgent therefore reframes repurposing from passive pattern recognition on a static graph to **active evidence-seeking reasoning** [2510.05764].

The output of a query is not merely a scalar score. Instead, RareAgent defines

$$
\mathcal{C}^* = \langle (c_1, G_{E,1}), \dots, (c_k, G_{E,k}) \rangle,
$$

where each $c_i$ is a candidate and each $G_{E,i}$ is a **task-specific evidence graph** justifying the proposed link. The learned object is thus a reasoning policy

$$
\pi : (q, r_{\text{target}}) \mapsto \mathcal{C}^*,
$$

rather than a static predictor $f(q,c)$ [2510.05764].

## 3. Multi-agent architecture and evidence-graph formalism

RareAgent is organized around four LLM-based agents: **Principal Investigator (PI)**, **Explorer**, **Proponent**, and **Skeptic**. The Explorer seeds plausible hypotheses using a KG+GNN retrieval model. The Proponent builds mechanistic and clinical support. The Skeptic searches for counter-evidence, safety concerns, and failure modes. The PI orchestrates the process, scores hypotheses, issues directives, and manages the self-evolution loop [2510.05764].

The central shared object is the **Task-specific Evidence Graph (T-EGraph)**,

$$
G_E = (V_E, E_E, \tau, \rho),
$$

where $\tau$ types nodes as query, hypothesis, or evidence, and $\rho$ types directed edges as entails, supports, or refutes. Each edge also carries a confidence weight $w \in [0,1]$. Nodes can encode candidate hypotheses, biomedical entities such as genes or pathways, and evidence items such as case reports or mechanistic studies. This makes the graph an auditable record of the reasoning process rather than an implicit latent state [2510.05764].

The paper’s iterative refinement algorithm begins with Explorer-generated hypotheses and an initial $G_E^{(0)}$. Proponent and Skeptic then propose graph updates, which the PI merges through a graph manager:

$$
G_E^{(t+1)} = \mathcal{M}\Big(G_E^{(t)}, \Delta G_{E,\text{pro}}^{(t)}, \Delta G_{E,\text{ske}}^{(t)}\Big).
$$

Hypothesis nodes are scored by an aggregation operator,

$$
s_t(v_h) = \mathcal{A}\Big( \sum w_{\text{sup}}, \sum w_{\text{ref}}, C_{\text{mech}}, D_{\text{path}}, \dots \Big),
$$

where the arguments include aggregated supporting and refuting weights, mechanistic connectivity, and disjointness of evidence paths. Iteration terminates when rankings stabilize,

$$
\max_i |s_{t+1}(v_{h_i}) - s_t(v_{h_i})| \le \delta_{\text{stop}},
$$

or when the round budget is exhausted [2510.05764].

Conceptually, this architecture makes RareAgent closer to a policy over graph-construction actions than to a conventional link predictor. The Proponent may add chains of the form drug $\rightarrow$ target $\rightarrow$ pathway $\rightarrow$ phenotype $\rightarrow$ disease, whereas the Skeptic may insert contraindications, conflicting studies, or off-target toxicity evidence. The PI can interrupt unproductive exploration, reprioritize safety or mechanistic depth, and reweight the graph-scoring emphasis as the debate evolves [2510.05764].

## 4. Self-evolution, textual feedback, and heuristic transfer

A defining feature of RareAgent is its **self-evolutionary loop**. After each investigation, the PI issues a **Credit Assignment Report** identifying pivotal, redundant, or misleading steps. This report is used to rewrite each agent’s instructions:

$$
P_{\text{agent}}^{(k+1)} \leftarrow \mathcal{U}\Big(P_{\text{agent}}^{(k)}, R_{\text{final}}^{(k)}\Big).
$$

The paper characterizes this as prompt-level policy refinement driven by natural-language critique rather than supervised labels or explicit RL rewards [2510.05764].

RareAgent also distills successful reasoning paths into a reusable **heuristic library**. When recurrent patterns appear across high-quality investigations, the PI abstracts them into conditional rules and stores them as

$$
\mathcal{L} \leftarrow \mathcal{L} \cup \{H_{\text{new}}\}.
$$

For a new query, relevant heuristics are retrieved and injected into the initial instructions of the Explorer and PI. The intended effect is transfer of “scientific intuition” across related rare-disease investigations without rebuilding all reasoning patterns from scratch [2510.05764].

The reasoning styles encouraged by this loop are explicitly plural: mechanistic or causal reasoning, clinical and safety reasoning, analogical reasoning across related diseases, literature-based aggregation, and adversarial stress testing. The transparency claim of the paper rests on the fact that the T-EGraph, the debate transcript, and the PI’s scoring rationale remain inspectable. This differs sharply from black-box GNN scores or opaque KG embeddings, because the final candidate ranking is accompanied by an explicit support/refutation structure [2510.05764].

## 5. Empirical performance, ablations, and case studies

RareAgent is evaluated on three datasets: a rare-disease drug-repurposing benchmark derived from the **100,000 Genomes Project** and **clinicaltrials.gov**, **PrimeKG** as the background biomedical KG, and **BioHopR** for multi-hop biomedical reasoning. After filtering, the 100kGP-based repurposing task contains **230 diseases, 74 drugs, and 1,188 candidate pairs** [2510.05764].

On the rare-disease **indication** task, the paper reports the following comparison:

| Method | AUPRC | AUROC |
|---|---:|---:|
| TxGNN | 0.373 | 0.552 |
| gpt-4o | 0.421 | 0.594 |
| RareAgent | **0.438** | **0.662** |

RareAgent also attains **P@10 = 0.04** and **R@10 = 0.27**. The paper summarizes this as an **18.1%** improvement in indication AUPRC over reasoning baselines and notes that RareAgent surpasses **o3-mini (w.Con)** despite using a smaller base model. On the contraindication task, all systems have near-zero top-$K$ precision and recall, but RareAgent still achieves the best ranking with **AUPRC 0.289** versus **0.283** for the best baseline. On **BioHopR**, RareAgent reports **Prec\_HOP1 = 33.87**, **Prec\_HOP2 = 17.68**, **BOTH\_COR = 9.74**, and **BOTH\_WR = 56.52**, exceeding the reported single-agent LLM baselines on both hop precision metrics [2510.05764].

Ablation studies show that the paper’s improvements are not attributable to a single component. Full RareAgent achieves **AUPRC 0.4381** and **AUROC 0.6623**. Removing debate yields **0.4067/0.6364**; removing the Skeptic yields **0.4314/0.6570**; removing PI interrupts yields **0.4145/0.6364**; removing textual feedback yields **0.3018/0.5556**; and removing heuristic transfer yields **0.3877/0.6518**. The largest degradation comes from deleting textual feedback, which the authors interpret as evidence that self-evolution is decisive. Across three self-evolution rounds, AUPRC rises from **0.438** to **0.463** and AUROC from **0.662** to **0.750** [2510.05764].

The principal qualitative case study is **ARVC–Flecainide**. RareAgent proposes Flecainide for **Arrhythmogenic Right Ventricular Cardiomyopathy**, a case in which the graph contains no established drug therapies. The Proponent builds support through sodium-channel blockade and suppression of ventricular ectopy, while the Skeptic highlights pro-arrhythmia and negative inotropic risks, and flags alternatives such as Dronedarone and Digoxin as high-risk or contraindicated. The paper then compares this reasoning path to the later clinical trial **NCT03685149**, which RareAgent did not access during its run and which reported approximately **72% reduction in ventricular ectopic beats versus placebo** with **no significant pro-arrhythmic signal**. The authors use this case to argue that RareAgent’s evidence-graph and Skeptic-driven pruning can be both predictive and safety-aware [2510.05764].

## 6. Other rare-disease systems discussed under similar names

The plural **RareAgents** names a different framework: a patient-centered, autonomous multi-agent MDT system for rare-disease **differential diagnosis** and **medication recommendation**. It simulates a multidisciplinary team of LLM-powered physician agents built on **Llama-3.1-8B/70B**, uses predefined roles from **41 medical departments**, includes dynamic long-term memory and tool use, and is evaluated on **RareBench-Public** and the newly introduced **MIMIC-IV-Ext-Rare** dataset. The best reported diagnosis configuration, RareAgents with **Llama-3.1-70B**, achieves **Hit@1 0.5589**, **Hit@3 0.6867**, **Hit@10 0.7811**, and **MR 1.0**; on treatment it reports **Jaccard 0.4108**, **F1 0.5563**, **DDI 0.0796**, and **\#MED 13.17** [2412.12475].

**RDMA**, or **Rare Disease Mining Agents**, is an agentic framework for mining rare diseases and phenotypes from EHR notes. It performs entity extraction, verification, implication reasoning, ontology matching, and dataset refinement; it is designed for local deployment on standard hardware to reduce privacy risk. The paper reports **F1 0.65** for phenotype extraction with **Mistral 24B** in 4-bit quantized form, **F1 0.39/0.48/0.59** for rare-disease mention extraction under different label sets, **up to 10× reduction** in inference cost, and **63%** reduction in human re-review workload in refinement, with Cohen’s $\kappa$ rising from **0.46** to **0.81** when RDMA is used with human oversight [2507.15867].

**AgentODE** is not formally named RareAgent, but its technical exposition explicitly frames itself as guidance for building a “RareAgent” for **rare diseases / small cohorts**. It jointly discovers ODE structure and infers parameter distributions from **population-level summary statistics only**, and includes a clinical study on **recessive dystrophic epidermolysis bullosa (RDEB)** with **231 observations across 46 patients**. The paper’s emphasis is mechanistic modeling under privacy constraints rather than diagnosis, repurposing, or EHR coding [2607.00733].

Finally, the string **“RareAgent”** appears in discussion of **ReAgent**, a backdoor defense for LLM agents, but the ReAgent paper states explicitly that the correct name is **ReAgent** and that “RareAgent” is best interpreted as an informal or mistaken variant. ReAgent operates in a thought–action loop, checks thought–action and instruction–plan consistency, and reports reductions of attack success rate by **up to 90%** in database operation tasks [2506.08336].

## 7. Limitations and broader significance

The RareAgent drug-repurposing paper is explicit about several limitations. Its reasoning quality depends on the factuality and reliability of the underlying LLM; hallucination can affect evidence selection and weighting. Distilled heuristics may overfit to particular disease classes or mechanisms. Background resources such as PrimeKG and clinical trials are incomplete and biased toward well-studied entities. Multi-agent debate can struggle in the presence of sparse, noisy, or conflicting evidence. Scalability is also a concern when moving from per-query investigations to much larger disease sets or repeated updates [2510.05764].

Within those constraints, RareAgent’s broader significance lies in its task reformulation. The paper presents it not as a stronger score function over a fixed graph, but as a framework that converts rare-disease repurposing into **active, evidence-seeking reasoning** with explicit support, refutation, and entailment structure. This suggests a general pattern for low-resource biomedical inference: when direct relational supervision is weak or absent, performance may depend less on deeper message passing than on the ability to assemble, criticize, and reuse mechanistically plausible evidence paths. In the specific context of rare diseases, that design choice aligns RareAgent with a wider movement toward agentic systems that combine planning, memory, tools, and auditable intermediate reasoning, even though those adjacent systems target different clinical or scientific endpoints [2510.05764][2412.12475][2507.15867][2607.00733].

Source: https://www.emergentmind.com/topics/rareagent